ICON Public Limited Company(ICLR)Company Profile & BusinessNASDAQ
Business, leadership and ownership
Company Profile
Business overview, scale, and footprint
Business Overview
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization.
In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for ICON Public Limited Company (ICLR) between Aug 7, 2026 and Sep 17, 2026 consists of 55 total transactions. Among these, company executives and board members conducted 18 buys (totaling 28,536 shares) and 37 sells (totaling 23,711 shares). This activity resulted in a net change of 4,825 shares, reflecting net buying interest with an estimated net sales value of $4.03M.
55 insider transactions found. Showing 10 of 55 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| Murphy Ronan Martin | Director | -5,005 | $175.00 | Sep 17, 2026 |
| McCague Eugene Pacelli | Director | -3,255 | $175.00 | Sep 17, 2026 |
| CLIMAX JOHN DR | Director | -5,005 | $175.00 | Sep 16, 2026 |
| Whitaker Anne Clem | Director | -88 | $162.72 | Aug 11, 2026 |
| Whitaker Anne Clem | Director | -96 | $163.77 | Aug 11, 2026 |
| Whitaker Anne Clem | Director | -590 | $164.47 | Aug 11, 2026 |
| Whitaker Anne Clem | Director | -67 | $165.51 | Aug 11, 2026 |
| O'Neill Julie | Director | -95 | $162.72 | Aug 11, 2026 |
| O'Neill Julie | Director | -105 | $163.77 | Aug 11, 2026 |
| O'Neill Julie | Director | -73 | $165.51 | Aug 11, 2026 |
Explore More Analysis for ICLR
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.